{
  "report_rows": [
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$4.39B vs. cons $4.43B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.96 vs. cons $2.90",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Book-to-bill",
      "prediction": "MISS",
      "answer": "pred ~0.95x vs. cons 1.00x",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$18.20B vs. cons $18.20B (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Non-GAAP diluted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$12.30 vs. cons $12.30 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating cash flow guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$1.80B vs. cons $1.80B (FY2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -1.2,
  "day5_path": "STABILIZE",
  "day5_rationale": "A sub-1.0x book-to-bill and ~$4.39B revenue versus $4.43B consensus would initially outweigh the EPS beat. With FY2026 revenue held near $18.20B, the implied H2 quarterly average rises to ~$4.71B versus ~$4.39B in Q2; however, unchanged FY2026 EPS of ~$12.30 versus $12.30 consensus limits estimate cuts, allowing the reaction to stabilize.",
  "day5_confidence": "LOW"
}